641 related articles for article (PubMed ID: 1646112)
1. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.
Tamura S; Funato H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
Eur J Immunol; 1991 Jun; 21(6):1337-44. PubMed ID: 1646112
[TBL] [Abstract][Full Text] [Related]
2. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.
Tamura SI; Asanuma H; Ito Y; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T; Oya A
Eur J Immunol; 1992 Feb; 22(2):477-81. PubMed ID: 1537382
[TBL] [Abstract][Full Text] [Related]
3. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.
Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780
[TBL] [Abstract][Full Text] [Related]
4. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
[TBL] [Abstract][Full Text] [Related]
5. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza.
Tamura S; Funato H; Hirabayashi Y; Kikuta K; Suzuki Y; Nagamine T; Aizawa C; Nakagawa M; Kurata T
Vaccine; 1990 Oct; 8(5):479-85. PubMed ID: 2251874
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
7. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
[TBL] [Abstract][Full Text] [Related]
8. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
9. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
Asahi-Ozaki Y; Yoshikawa T; Iwakura Y; Suzuki Y; Tamura S; Kurata T; Sata T
J Med Virol; 2004 Oct; 74(2):328-35. PubMed ID: 15332283
[TBL] [Abstract][Full Text] [Related]
10. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
Liew FY; Russell SM; Appleyard G; Brand CM; Beale J
Eur J Immunol; 1984 Apr; 14(4):350-6. PubMed ID: 6609824
[TBL] [Abstract][Full Text] [Related]
11. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
13. Studies on the usefulness of intranasal inactivated influenza vaccines.
Tamura S
Vaccine; 2010 Aug; 28(38):6393-7. PubMed ID: 20493820
[TBL] [Abstract][Full Text] [Related]
14. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
[TBL] [Abstract][Full Text] [Related]
15. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
[TBL] [Abstract][Full Text] [Related]
16. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.
Chen J; Fang F; Li X; Chang H; Chen Z
Vaccine; 2005 Jul; 23(34):4322-8. PubMed ID: 15925433
[TBL] [Abstract][Full Text] [Related]
17. TH cells primed during influenza virus infection provide help for qualitatively distinct antibody responses to subsequent immunization.
Marshall D; Sealy R; Sangster M; Coleclough C
J Immunol; 1999 Nov; 163(9):4673-82. PubMed ID: 10528164
[TBL] [Abstract][Full Text] [Related]
18. Defense mechanisms against influenza virus infection in the respiratory tract mucosa.
Tamura S; Kurata T
Jpn J Infect Dis; 2004 Dec; 57(6):236-47. PubMed ID: 15623947
[TBL] [Abstract][Full Text] [Related]
19. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
[TBL] [Abstract][Full Text] [Related]
20. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y
Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
